[HTML][HTML] FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer
T Conroy, P Hammel, M Hebbar… - … England Journal of …, 2018 - Mass Medical Soc
Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
…, E Gamelin, H Gascan, M Hebbar… - Blood, The Journal …, 2007 - ashpublications.org
Tumor-associated macrophages (TAMs), the most abundant immunosuppressive cells in
the tumor microenvironment, originate from blood monocytes and exhibit an IL-10 high IL-12 …
the tumor microenvironment, originate from blood monocytes and exhibit an IL-10 high IL-12 …
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
…, M Guillet, J Forestier, E Terrebonne, M Hebbar… - JAMA …, 2022 - jamanetwork.com
Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages
…, S Ponsoda, Y Delneste, M Hebbar… - … journal of cancer, 2009 - Wiley Online Library
Tumor‐associated macrophages (TAM) are M2d‐polarized cells (IL‐10 high , IL‐12 low ,
ILT3 high , CD86 low ) that accumulate in tumor microenvironment. TAM inhibit antitumor T …
ILT3 high , CD86 low ) that accumulate in tumor microenvironment. TAM inhibit antitumor T …
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on …
P Morel, M Hebbar, JL Lai, A Duhamel, C Preudhomme… - Leukemia, 1993 - europepmc.org
Although the prognostic value of cytogenetic analysis has previously been demonstrated in
myelodysplastic syndromes (MDS), karyotype had not been included in previously published …
myelodysplastic syndromes (MDS), karyotype had not been included in previously published …
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis
…, P Dumont, S Truant, FR Pruvot, M Hebbar… - Clinical cancer …, 2014 - AACR
Purpose: Metastasis and drug resistance are the major limitations in the survival and management
of patients with cancer. This study aimed to identify the mechanisms underlying HT29 …
of patients with cancer. This study aimed to identify the mechanisms underlying HT29 …
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
…, C Barone, LE Fein, AG Villanueva, M Hebbar… - The Lancet …, 2019 - thelancet.com
Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess …
The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study
…, D Goéré, M Guilbert, J Guiramand, M Hebbar… - Annals of …, 2011 - journals.lww.com
Objective: The aim of this retrospective study was to evaluate the survival impact of perioperative
chemotherapy (PCT) in patients with gastric signet ring cell (SRC) adenocarcinoma. …
chemotherapy (PCT) in patients with gastric signet ring cell (SRC) adenocarcinoma. …
Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer
M Ducreux, J Bennouna, M Hebbar… - … journal of cancer, 2011 - Wiley Online Library
A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used
in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our …
in France in the first‐line treatment of metastatic colorectal cancer (MCRC). The aim of our …
Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients …
T Conroy, P Hammel, M Hebbar, M Ben Abdelghani… - 2018 - ascopubs.org
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in
metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed …
metastatic pancreatic cancer for patients (pts) with good performance status. This trial assessed …